Avidin-biotin system for delivery of diagnostic agents

被引:93
作者
Sakahara, H [1 ]
Saga, T [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Nucl Med & Diagnost Imaging, Sakyo Ku, Kyoto 6068507, Japan
关键词
avidin; streptavidin; biotin; monoclonal antibody; radionuclide; pretargeting; radioimmunoimaging; radioimmunotherapy; radioimmunoguided surgery;
D O I
10.1016/S0169-409X(98)00101-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Radiolabeled monoclonal antibodies specific for tumor-associated antigens are used for the diagnosis and therapy of malignant tumors. However, the blood clearance of antibodies is slow and tumor-to-nontumor ratios of radioactivity in the current system are not high. To increase tumor-to-nontumor ratios, the concept of pretargeting has been proposed. The strategy is based on the separate administration of the monoclonal antibody and the radiolabel. Because avidin and streptavidin bind to biotin selectively with extremely high affinity, the avidin-biotin system has been applied for pretargeting. With this method, high tumor-to-nontumor ratios are reported, not only in animal experiments, but also in clinical trials. The avidin-biotin system is also used to reduce the background radioactivity of the directly labeled antibody as well as radioimmunoguided surgery. (C) 1999 Elsevier Science BN. All rights reserved.
引用
收藏
页码:89 / 101
页数:13
相关论文
共 77 条
[21]  
Hashmi M, 1995, DRUG METAB DISPOS, V23, P1362
[22]  
HNATOWICH DJ, 1987, J NUCL MED, V28, P1294
[23]   IMPROVED TUMOR-LOCALIZATION WITH (STREPT)AVIDIN AND LABELED BIOTIN AS A SUBSTITUTE FOR ANTIBODY [J].
HNATOWICH, DJ ;
FRITZ, B ;
VIRZI, F ;
MARDIROSSIAN, G ;
RUSCKOWSKI, M .
NUCLEAR MEDICINE AND BIOLOGY, 1993, 20 (02) :189-195
[24]  
Hu SZ, 1996, CANCER RES, V56, P3055
[25]   Biotinidase and its roles in biotin metabolism [J].
Hymes, J ;
Wolf, B .
CLINICA CHIMICA ACTA, 1996, 255 (01) :1-11
[26]  
KALOFONOS HP, 1990, J NUCL MED, V31, P1791
[27]   Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development [J].
Karacay, H ;
Sharkey, RM ;
Govindan, SV ;
McBride, WJ ;
Goldenberg, DM ;
Hansen, HJ ;
Griffiths, GL .
BIOCONJUGATE CHEMISTRY, 1997, 8 (04) :585-594
[28]  
Kassis AI, 1996, J NUCL MED, V37, P343
[29]  
KHAWLI LA, 1992, NUCL MED BIOL, V19, P297
[30]  
KHAWLI LA, 1993, ANTIBODY IMMUNOCONJ, V6, P13